Phio Pharmaceuticals Corp. Common Stock
PHIOPhio Pharmaceuticals Corp. (PHIO) is a biotechnology company that focuses on developing immuno-oncology therapies using its proprietary RNA interference (RNAi) platform. The company aims to enhance the body's immune response to cancer by targeting and modulating specific genes involved in tumor immune evasion.
Company News
The Merkel cell carcinoma market is expected to grow significantly between 2025-2034, driven by rising global incidence, increased awareness, and innovative treatment developments like immunotherapies and targeted therapies.
Phio Pharmaceuticals reported a Q2 2025 net loss of $2.2 million, with its lead candidate PH-762 showing promising early clinical results in cancer therapy. The company's INTASYL platform demonstrated positive safety and efficacy signals in gene-silencing cancer treatments.
The global retinoblastoma treatment market is projected to grow from $1.93 billion in 2023 to $2.03 billion in 2024, driven by factors like increased funding, cancer research, and technological advancements. The market is expected to reach $2.56 billion by 2028, growing at a CAGR of 5.9%.
--Fund invests in microcap equities --Fund invests in microcap equities
-PH-762 is Phio’s lead product candidate
